Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31217395 | 0.90 | PTPN11 (0.45) | HDAC6JAK2JAK1DYRK1AJAK3 | |
| SCHEMBL20507911 | 0.83 | HDAC6 (0.44) | HDAC6JAK2JAK1JAK3MAP4K4 | |
| SCHEMBL16991350 | 0.81 | DYRK1A (0.45) | HDAC6JAK2DYRK1AJAK3MAP4K4 | |
| SCHEMBL15509175 | 0.81 | DYRK1A (0.45) | HDAC6JAK2DYRK1AJAK3MAP4K4 | |
| SCHEMBL15205495 | 0.80 | MCHR1 (0.55) | JAK2JAK1MAP4K4HRH4HRH3 | |
| SCHEMBL390344 | 0.80 | MCHR1 (0.55) | JAK2JAK1MAP4K4HRH4HRH3 | |
| SCHEMBL390343 | 0.80 | MCHR1 (0.55) | JAK2JAK1MAP4K4HRH4HRH3 | |
| SCHEMBL28220125 | 0.80 | MAP4K4 (0.46) | HDAC6JAK2JAK1DYRK1AJAK3 | |
| SCHEMBL13569911 | 0.78 | GRM2 (0.43) | JAK2JAK1DYRK1AJAK3GRM2 | |
| SCHEMBL28890467 | 0.78 | GRM2 (0.43) | JAK2JAK1DYRK1AJAK3GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | HDAC6 134/4885JAK2 166/4885JAK1 474/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | HDAC6 105/4885JAK2 422/4885JAK1 356/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | HDAC6 134/4885JAK2 166/4885JAK1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.